<SEC-DOCUMENT>0001193125-23-047503.txt : 20230224
<SEC-HEADER>0001193125-23-047503.hdr.sgml : 20230224
<ACCEPTANCE-DATETIME>20230224073508
ACCESSION NUMBER:		0001193125-23-047503
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230224
FILED AS OF DATE:		20230224
DATE AS OF CHANGE:		20230224

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		23662359

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d437702d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of February, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three
International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&nbsp;&#9745;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&nbsp;&#9744;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February 24, 2023, Kazia Therapeutics Limited (the &#147;Company&#148;), in connection with the reporting of its change in auditor
pursuant to and in accordance with ASX Listing Rule 3.16.3, issued an ASX announcement titled, &#147;Change In Auditor.&#148; A copy of this release is attached hereto as Exhibit&nbsp;99.1 and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby incorporates by reference the information contained herein, including Exhibit&nbsp;99.1, into the Company&#146;s
registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;F-3</FONT> (File No. <FONT STYLE="white-space:nowrap">333-259224).</FONT> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d437702dex991.htm">ASX Announcement of Kazia Therapeutics Limited dated February&nbsp;24, 2023 </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Kazia Therapeutics Limited</B> (Registrant)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Karen Krumeich</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Karen Krumeich</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: 24 February 2023</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d437702dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g437702dsp3.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX ANNOUNCEMENT </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">24 February
2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CHANGE IN AUDITOR </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>S</B><B>y</B><B>dn</B><B>ey</B><B>,</B><B> </B><B>2</B><B>4</B><B> </B><B>Fe</B><B>b</B><B>ru</B><B>a</B><B>r</B><B>y</B><B>
</B><B>2</B><B>0</B><B>2</B><B>3</B><B> </B>&#150; Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), (<B>t</B><B>h</B><B>e C</B><B>o</B><B>m</B><B>p</B><B>a</B><B>n</B><B>y</B><B>),</B><B> </B>an oncology-focused drug development company, advises
that in accordance with ASX Listing Rule 3.16.3, BDO Audit Pty Ltd (<B>BD</B><B>O</B>) has been appointed as auditor of Kazia Therapeutics Limited, effective from the date of this announcement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The change follows the resignation of Grant Thornton Audit Pty Ltd (<B>G</B><B>r</B><B>a</B><B>n</B><B>t</B><B>
</B><B>Th</B><B>o</B><B>rn</B><B>t</B><B>o</B><B>n</B>) as auditor of Kazia Therapeutics Limited in accordance with section 329(5) of the Corporations Act 2001 (Cth)
(<B>C</B><B>o</B><B>r</B><B>p</B><B>o</B><B>r</B><B>a</B><B>t</B><B>i</B><B>o</B><B>n</B><B>s</B><B> </B><B>A</B><B>c</B><B>t</B>) and ASIC&#146;s consent to the resignation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The appointment of the new auditor of the Company was considered by the Board to be a matter of good corporate governance. Grant Thornton had held the
position as auditor for a number of years, and accordingly it was deemed appropriate to conduct a tender process to seek a new auditor. The Company confirms that it has received a letter of resignation from Grant Thornton and has also received the
consent of ASIC to their resignation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BDO&#146;s appointment is effective until the 2023 Annual General Meeting of the Company. In accordance with
section 327C of the Corporations Act, a resolution will be put to shareholders and the 2023 Annual General Meeting to appoint BDO as the auditor of Kazia Therapeutics Limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board would like to take this opportunity to thank Grant Thornton for its assistance and services to the Company over their years of service. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ENDS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in Sydney, Australia. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being
developed to treat multiple forms of brain cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed phase II study in glioblastoma reported promising signals of efficacy
in 2021, and a pivotal study for registration, GBM AGILE, is ongoing, with final data expected in CY2023. Other clinical trials are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these having reported
encouraging interim data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for
glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020, and for atypical teratoid / rhabdoid tumours (AT/RT) in June 2022 and July
2022, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical
data has shown EVT801 to be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno- oncology agents. A phase I study commenced recruitment in November 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit <U>www.kaziatherapeutics.com</U> or follow us on Twitter @KaziaTx. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g437702dsp3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g437702dsp3.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * %1'D<)
M&I=SP%49)H2OL)M)78Z6"6"3RYHGC?\ NNI!IM-:,(R4E=,=-:W%N%,\$D0;
M[N]2,_G0XM;H49QE\+N14B@H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * 'P0O<7$<$0S)(P11ZDG HV&
M;TW@W4X?$_\ 8.^!KCR_-\U7/E;-NXMDC.,>U1S*URN5WL \'WCW;V\%Y9W#
M?9#=Q&*0D3(.H7C.[@\'%',@Y69NKZ3/HMZ+.Y>-IQ&CNJ$GRRPSM.1U (S5
M)W):L:-KX/O[K3[6^$]M':SV\MP9'9@(DC;:=W'4G@ 9SFIYDM!J+W&6OA=[
MS1;G4X-4L&6VA\Z6'<X=!G !^7;DGH,T^:SL'+I<9/X7O[?PO!X@9X3:S/L$
M88^8H)8!B,8P2I[T<RO8.5I7,U[.2/3H;TLOERRO$H[@J%)_#YQ^M._05CH+
MGP%JMIY1DEMBLMB]\K!FQL10Q7I][!''3GK4J:*Y&BBOA>_;PJWB$/#]D5]A
M3<?,QG;NQC&,\=:?,KV%RNUR27PE?0Z0M^]Q:*QMA=BV,A\TQ$X#8QC\,YHY
ME>P<KM<GUCP3?Z-;7<SWEG<FS\O[3' [%X@^-I(*C@Y'3/6DIIC<&BI?^%K_
M $[0+#6)FB:"]("(C$NN1D;ACC(&1R::DF["<6E<FU7P?J&D64]Q--:RFV9$
MN8HI"SP%AE0W&/R)H4DP<6C/T?1[C6KJ:WMWC1XH'G/F$@;5&2. >:;=A)7+
MDGAB2UOH;.]U*RLYI(%G(E9_W><81L*<-@YQ2YNP^6VA+J_@Z^T:"^FFN;65
M;*2..3RF8G+KD8RHZ#KG%)23&XM$&L^%[_0M.T^]NGA:.]3<JQL2T?RJV&R.
M#AAZTU)/03BT8M42% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % &WX:TNUU.[E6Y)*QKD(#C=6U&"F]3CQ=:5**<2VWV/PUXG! 9X#'TZF//
M_P"K\C5^[2J&:Y\50\_S(]9UVUN]6LKB"(O';-DEA@OR#C]*52JI2370=##S
MA3E&3W)O$.OV6I6$=O;ABQ<,69<;:=6K&<;(G"X:=*;E(FU7PYI]GHC7$3L)
M8U!#ELA_PJJE&,871%'%5)U>5['(UR'J!0 4 % !0 4 % !0 >PH * "@ H
M* "@ H * "@ H * #V% !0 4 % !0 4 % !0 4 % !0 4 % &WX1N+&R\3V5
MYJ,@2VMF,QR"=S*"5 ^K8J97:LBHV3U.GN=?T>^U7P_J=OJ<^FSP0/!([#S'
MBVY\LMA<,#D@X'2HLTFB[IM,0ZQH%GXLCURWE@\ZSL_,=+9&2*XNN1A00"%Y
MR>G2BSM8+I.YC>)+NUN+_6+G3M6!M;XQSM P.YV))*DX_A.?PQ515K7)EUL;
M=IK^DS^!K'PY<WBQ"2TFWOM/[J42[XP<#H>:FS4KE)KEL9DXTY? ]O8V.M6D
M<C@W-Y&XD$DL@'RQC"XP![]3FGKS7:%IRV1LWWB#PY/I&H:'%-(%338HHK@M
M^ZDDB^8 +MR"69N2:233N-M6L<7<?\BEI_\ U^W'_H$-7U(Z'H(\7:++9:I:
MS7B\:8$M&VGF1H-CIT]0OY5GRO0TYD4H_$'AQ=(_L$S2!3I/D&XW?N?._P!9
M]W;G._C.<?SI\KO<5U:QGR:IHTG@C['=Z@E[(ELHMHI(2)[:;=\RA\8\O'J:
M=GS"NN6QH>(]9T:7_A(9K;58;A]86UBBC1'S&$V[F<D ?P\8S2BGIY#;6HNL
M^)O#U[I^K6%H\J_9S ]HTC9CD,6% 50H*Y7/4_E0HM68.2V(];U71[BP\2W%
MEK$#R:M-;S1PLCJ\80DD'Y<9R?7H.M"35M ;6ID^'=9BTSQ?J=]>:BD[-!.%
MN=A*RN1P<8[GU%.2NK(F+L[F@EWX?O?&O]ORZA"@DMQ="&<.52ZP!L; )P#\
MW'TI6:C8JZYKE87=A_8^I:??:W!<SWNH03//&'P5YWMRH/&?2G9WND*ZM9LM
M>*?$>AZ[HFK6]LTL4T5ZD]OYK9$HQY9V *-HVA3@THQ::'*2://JU,@H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@#4\//:1ZQ$UYM$>#@O]T-
MVS6M)Q4O>.;%*;I-0W+/B2YM!JJ2:;(JN$^=X3@9^HJJSCS7B9X6$_9VJ?B5
M+;2;B_MVN?-&23C<<EOQKS:N+C3GRL^CPF4U,31]I%I=D6-,TZTN;)Y)F^<$
M@_-C96.(Q%2G42CM^9VY=@,-7P\IU7KZ[%:ST>6\A:5)%502%SWK6KBHTI*+
M1QX3*JF*INI&22Z>96CF;S8H;F21K>-QN3<2 ,\X%=L97M?8\:=/EO9:G3^(
M[C2)-'5;9H&ER/+$6,@=\XZ<5U5G!QT/-PL:RJ>]>QR%<AZ@4 >Y?!ZWAD\'
MSL\*,WVM^2H)^ZM<]3<Z*>QPT7A*?Q1\2M7LX5\JSBO96GD4<(N\\#W/;_ZU
M:<W+%&?+>3/0O&FN:7X'\.Q:=I]K +R2/9;Q[ =B]"[>OX]3^-913D[LTDU%
M61X)72<X4 >E?!_P]]NUF;69TS#9#;'D<&0C^@_F*RJ2LK&M-:W,+XC>'O\
MA'_%<ZQ)MM+K]_#@<#)Y7\#G\,54)71,U9G)59 J$!U)Z T ?0*?$7P.$4?;
M4' X^R2<?^.US<DCIYXG374^GVFD2ZE)!&((X3,=T>TX ST(X/M4*][%;*Y\
MO7UV]_J%Q>2*JO/(TC!1@ DYXKK2MH<K=Q^E@'5[($9!G3(/^\*'L"W/</BU
M;PQ^"'9(45A<1\A0#WKGI_$;U/A/!:Z3G"@#TKX/^'OMVLS:S.F8;(;8LC@R
M$?T'\Q6525E8UIK6YS_Q$T-="\8W<,2;;>?$\0[ -U'X$$54'=$S5F<K5D!0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 /,TK6Z0%R8D8NJ=@2 "?\
MQT?E0 R@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H [&;^Q?^$5/E^1YGE#'3?O\ Y]:['[/V>AY4?;_6-;VO
M\K'/Z/907L[K,3A5R%!QFO'Q5:=**<3ZS*L)2Q522JO9;"W%S-IL\UI:SGR0
M>.A(R/6BG3C7BJDUJ57Q%7 U)X>A/W?R,X D' ..]=AXURQ;ZA<VL31PR;5;
MMCI6-2A3J.\D=M#'5\/!PIRLF:-SIEI'I N%D)DV@[L_>)[5QT\14=;D:T/7
MQ&78>&"]LG[UD[WW)O"AT\74WVWRP^T>7YF,>_7OTKVJ'+?WCXW&>TY5R&?K
M9M3K%Q]CV^3D8V],XYQ^-9U+<[Y3?#\_LES[F?69N>[?!O\ Y$V?_K\?_P!!
M6N>K\1T4]CL;2QMM-M+Z73($EFFEEG8;@/,E).03VYX]L5G>^Y=K;'S3KVH:
MAJFMW5UJFX79<AT88V8XV@=@.E=:22T.5MMZF=3$.CC>618XU+.Y"JHZDGM0
M!]$6HM?AS\/D:90SVZ!I%!P9)6[?GQ]!7+\<CI^")2^(>DP^*?!":G98DDMT
M%S"PZLA&6'Y<_A3@^65A35XW/ JZ3G"@#L?AMX:_X2#Q/&\R;K.RQ-+D<,?X
M5_$_H#6<Y61<(W9VWQB\1_9K"#0;=\27&)9\'H@/RC\2,_A44H]32H[:'C%;
MF!;TK_D,6/\ UW3_ -"%)[#6Y[G\7?\ D17_ .OB/^M<]/XC>I\)X#72<XZ.
M-Y9%CC4L[$*JCJ2>U 'T1:BU^'/P]1IU#/;H&D4'!DE;M^?'T%<OQR.GX(F-
M\3M)A\1>#[?7K']XULHF5A_%$P&?RX/X&JIOE=F*:NKH\.KH.<* "@ H * "
M@ H * "@ H * -+0+&+4M;MK.8$I)N!"G!X4D?J*3=D5%7=A]WID7]I'3[5E
M62W0K/+*^T%Q]['L#P.YQGO23TN%M; /#]YB_#O!')8;O.B:0!@%QDCU&2!1
M=!RCFT&ZGN6C@BBC811N(S,"S;HPXQZY'/MG'I1<+#_#4%A=WSVU]:-.#%)(
MK+*4V[(V;'OG HE=;!&Q);:-'JVGO/8Q+#.]V(8HGFZ@H2%&>I)%%[;@E?8H
M#1[LZ=]MVIY?E^;MW#=LW;-V/3=Q3NKV%;2Y:/AB_&H-8![8W*L$\L3*27)(
M"_4X_EG%+F6X^5[%==$NWTX7R^7Y91I OF#>54X8X]J=];"MI<E3PYJ+R6T:
MI&7N)8H0N\91I!E WID<_A2YD/E8NGZ!+>H)'N(K>-K>2=&<]0F01QTY%#=@
M2N,_L>>80E$CA3[,)VDDE 7:6VY)/3)P,47"PQM#O8[>6:3RHQ&\B8:506*8
MWA?7&1]>V:=T%F#64(\-I? 'SC=M$>>-H0'^9HOK85M"V/#5[=7#);Q11<Q(
M$:8?,SQ[U )[D GVZ4N9(?*R :+/'YPD6)U^S+.LHE^54,BINXZ\DC'U]*+A
M8FN/#-S'J]Y80SPRBVF$)E+;%+DD*O/<X/'M1S:7#EUL+IV@/)%/-=A41;:>
M1$,@#DHIYQZ;AC\#0V"B8=42% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M3G^R!IWRJ^>?E7H!T[#%:*<4K&3A)NYYE+$T,SQ/PR,5/U%;&19TK_D,6/\
MUW3_ -"%)[#6Y[G\7?\ D17_ .OB/^M<]/XC>I\)X#72<YWOPH\/?VKXF_M"
M9,VVG@2<C@R'[H_#D_@*RJ.RL:4U=W/6O$,OA34!_9VNWMD?)8.89;G85.."
M0".Q_6L8\RU1L^5Z,LZ,WA^736TK2+BUGM(D*M#%,) JMG@\DX/-#O>[&K;(
M^=_%.AOX=\1WFFMG9&^8F/\ $AY4_E^M=,7=7.:2L[&/5$A0 4 % !0 4 %
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MN*L<[J%]+J6I7-].%$MQ*TKA1@ DY.*I*RL2W=W.PL/BQXBL-/AL]MI.L2;
M\T;%B/<AAFH=-,M5&CB9Y?/N))=B)O8MM085<GH!V%:;&9TGACQUJ7A.TGM[
M"VM'$S[V>5&+=, 9!''^)J)04MRXS<=C O[ZXU/4+B^NGWSSN7<^YJDK:$MW
MU+>@:]>^&]6CU&P*^:@*E7&58'J"/\]*32:LQI\KNB]XH\87_BUK9K^WMHWM
MPP5H4()!QP<D^E*,5'8)2<C%L;M]/O[>\C1'>"19%6094D'/(]*IJ^@D['>_
M\+E\1?\ /KI__?M__BJS]DC3VC#_ (7+XB_Y]=/_ ._;_P#Q5'LD'M&>?32M
M-/)*^-SL6./4UJ9"V\S6UQ%.F-\;!USTR#F@>QU7B+XBZOXFTHZ=>P6J0EP^
M8D8'(^I-1&"B[HIS;5CD:L@ZOPU\0-4\+::UC86UFR-(9&:1&+$D =01Z5$H
M*3NRXS<59'.:A?7&IZA<7UT^^>=R[GW-4E96);OJ7_#GB2_\+ZF;[3]A=D*,
MD@)5@?4 CN!2E%25F.,G'8F\3^*KWQ7=P7-]!;QRPIL!A4C(SGG)/O\ G1&*
MCL$I<QA51(4 % !0 4 % !0 4 % !0 ^"%[FXB@B7,DC!%'J2<"C89L)X?0:
MI?6LMVPAM8//$L4.\R(=NTA<CJ'!ZU-]!\NHY_#3!=3V789K-8W1=F#(&0OC
MK\I"@DCGD$4<P<I3?3$AU,VDUVD:+&)#(RGN@;  ZGG IWT"VMBRF@Q_:[VT
MEO@D]JCOQ&2K*J[NO;TQCK2N'*0VVB/<Z;]J$Z*[+*\<1!RZQ@%SGH.,_D:+
MV86T)+K01974=O<WL<3'<)"R,-A49../F]!CN/QHO<+6&?V*$U=[":]BCVJK
M*Y4G=NV[0!US\PR.V#Z47TN%M;$LGAV2#3FN9)F+B9X0L<19=RD#E^@!)XHY
M@Y2'4-&_LZ2/S+D-"9WMWD5#\KH5WX'<?,"/7VH3N#5BY'X926=EBO6>-;-;
MLE;<E\&0(%V@]?F!^AI<P^4H)I#R:9>WXE BMG"J&4@R?, <>F-RY^M5?6PK
M:7,ZF2% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MVMQ4TUC:K/+<0P"0$QK(3EP/H./QH4-+MB=5*7*DV(=/9+!+MYHD#@E$.=S
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 *CO&X>-V1AT*G!%"=MA-)JS+FFZG-IM^+M1YC8(8,?O ^]7";A*
MYE5HJK#D+6I>()]0O;>X6-8OLYW(N<\Y!Y_(54ZKDT^QG2PT:<7&][DFK>))
MM4LUMC L2Y!8@YSC^5.I6<U8FAA(T9<U[F,9'9 A=B@Z*3P*QN==DG<;0,*
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
K * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
